Boston Scientific CMO Discusses Future Of Watchman
This article was originally published in Clinica
Executive Summary
Boston Scientific worked long and hard to earn the US FDA’s approval of the Watchman left-atrial appendage closure device, including three panel meetings and two large studies, but Ken Stein, chief medical officer for cardiac rhythm management, says the firm is now is a very good position to accelerate adoption.